Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study

Area of Science:

• Gastroenterology
• Nephrology
• Pharmacology

Background:

• Constipation is a common and debilitating issue for hemodialysis patients, negatively impacting their quality of life (QOL).
• Elobixibat, an ileal bile acid transporter inhibitor, enhances colonic motility and secretion, presenting a potential novel mechanism for treating constipation in this population.
• Previous research has not reported on the specific effects of elobixibat on the QOL of hemodialysis patients with chronic constipation.

Purpose of the Study:

• To evaluate the efficacy of elobixibat in improving the quality of life (QOL) of hemodialysis patients experiencing chronic constipation.
• To assess the impact of elobixibat on key indicators of constipation and patient-reported outcomes.

Main Methods:

• A multicenter, observational study involving 27 hemodialysis patients diagnosed with functional constipation.
• Patients received elobixibat 10 mg/day for 4 weeks, with QOL assessed using the Japanese version of the Patient Assessment of Constipation-Quality of Life (PAC-QOL) questionnaire at baseline and follow-up.
• Bayesian statistics were employed to analyze the data and confirm the significance of the findings.

Main Results:

• Significant increases in spontaneous bowel movements per week (from 2.6 to 4.1) and improvements in stool form (Bristol Stool Form Scale) were observed (p < 0.001).
• Substantial reductions in PAC-QOL scores were reported across all domains: physical discomfort, psychosocial discomfort, worries/concerns, and overall satisfaction (p < 0.001).
• The total PAC-QOL score decreased significantly, indicating a marked improvement in patient-reported QOL.

Conclusions:

• Elobixibat treatment led to significant improvements in the QOL of hemodialysis patients with chronic constipation, as measured by reduced PAC-QOL scores.
• The findings suggest that elobixibat is a promising new therapeutic option for managing constipation in hemodialysis patients.
• Further research may explore elobixibat's long-term effects and its role in improving overall patient well-being in this vulnerable population.